Literature DB >> 9392491

Leptin sensitivity in nonobese glucagon-like peptide I receptor -/- mice.

L A Scrocchi1, T J Brown, D J Drucker.   

Abstract

Glucagon-like peptide I (GLP-I) stimulates glucose-dependent insulin secretion and inhibits food intake in the central nervous system. Because leptin reduces food intake but inhibits insulin secretion, we examined leptin action in mice with a null mutation in the GLP-I receptor. Intracerebroventricular leptin administration inhibited food intake in both wild-type and GLP-I receptor (GLP-IR) -/- mice, and daily intraperitoneal administration of leptin for 2 weeks produced comparable reductions in food intake and body weight in control and GLP-IR -/- mice. Glucose tolerance was improved in both wild-type and GLP-IR -/- mice, whether pair fed or leptin treated; however, blood sugars were significantly lower in the leptin-treated GLP-IR -/- mice following oral glucose challenge (P < 0.01). Glucose-stimulated insulin was reduced in both pair-fed and leptin-treated mice (P < 0.01-0.001); however, insulin levels were significantly lower in leptin-treated versus pair-fed GLP-IR -/- mice (P < 0.01). A single leptin injection had no effect on glucose tolerance in GLP-IR -/- mice, but decreased hepatic PEPCK mRNA in both wild-type and GLP-IR -/- mice. The improvement in blood glucose excursion, despite lower levels of glucose-stimulated insulin in lean leptin-treated GLP-IR -/- mice, suggests that leptin may have beneficial effects on control of blood glucose in the absence of obesity. Furthermore, the greater effects of leptin on glucose and insulin in leptin-treated versus pair-fed GLP-IR -/- mice raises the possibility that disruption of GLP-I signaling modifies the sensitivity to leptin in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9392491     DOI: 10.2337/diab.46.12.2029

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  5 in total

Review 1.  GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities.

Authors:  Jonathan D Roth; Mary R Erickson; Steve Chen; David G Parkes
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  GLP-1 and energy balance: an integrated model of short-term and long-term control.

Authors:  Jason G Barrera; Darleen A Sandoval; David A D'Alessio; Randy J Seeley
Journal:  Nat Rev Endocrinol       Date:  2011-06-07       Impact factor: 43.330

3.  Leptin receptor-expressing nucleus tractus solitarius neurons suppress food intake independently of GLP1 in mice.

Authors:  Wenwen Cheng; Ermelinda Ndoka; Chelsea Hutch; Karen Roelofs; Andrew MacKinnon; Basma Khoury; Jack Magrisso; Ki Suk Kim; Christopher J Rhodes; David P Olson; Randy J Seeley; Darleen Sandoval; Martin G Myers
Journal:  JCI Insight       Date:  2020-04-09

4.  Leptin ameliorates ischemic necrosis of the femoral head in rats with obesity induced by a high-fat diet.

Authors:  Lu Zhou; Kyu Yun Jang; Young Jae Moon; Sajeev Wagle; Kyoung Min Kim; Kwang Bok Lee; Byung-Hyun Park; Jung Ryul Kim
Journal:  Sci Rep       Date:  2015-03-23       Impact factor: 4.379

Review 5.  GLP-1 physiology informs the pharmacotherapy of obesity.

Authors:  Daniel J Drucker
Journal:  Mol Metab       Date:  2021-10-06       Impact factor: 7.422

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.